New drug combo aims to control ER+ breast cancer
NCT ID NCT03285412
First seen Dec 30, 2025 · Last updated May 13, 2026 · Updated 19 times
Summary
This study tests a drug called ribociclib combined with standard hormone therapy for people with ER-positive breast cancer. The goal is to see if the combination can clear tumor DNA from the blood and help control the disease. About 120 postmenopausal women with early-stage breast cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Mass General/North Shore Cancer Center
Danvers, Massachusetts, 01923, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.